Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

The 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) were exercised for 1,616,600 shares between 1 May 2026 and 22 May 2026. As a result, the number of stock acquisition rights remaining unexercised decreased from 72,045 to 55,879.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
1616600
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the large-scale exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Shares delivered since the beginning of the month: 1,616,600 shares (1,616,600 new shares and 0 transferred treasury shares)

発行済株式総数

Stock acquisition rights exercised since the beginning of the month: 11.88% of the total number issued (the ratio to the number of issued common shares based on the number of shares delivered was not disclosed)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Subject to an exercise price adjustment clause. The exercise prices are stated as ¥92.0, ¥87.4, ¥86.5, ¥85.6, ¥82.8, ¥81.0 and ¥81.9, but details of the adjustment clause and the floor price were not disclosed
Number of Stock Acquisition Rights
Equivalent to 11.88% of the total 16,166 stock acquisition rights issued. Number of stock acquisition rights remaining unexercised as of the end of the previous month: 72,045; number remaining unexercised at present: 55,879
Most recent equity financing
Timing 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the large-scale exercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 1,616,600 shares (1,616,600 new shares and 0 transferred treasury shares)
Dilution RateStock acquisition rights exercised since the beginning of the month: 11.88% of the total number issued (the ratio to the number of issued common shares based on the number of shares delivered was not disclosed)
Total number of issued shares74,459,300 shares (as of the end of the previous month) → Not disclosed
Exercise priceSubject to an exercise price adjustment clause. The exercise prices are stated as ¥92.0, ¥87.4, ¥86.5, ¥85.6, ¥82.8, ¥81.0 and ¥81.9, but details of the adjustment clause and the floor price were not disclosed
Number of Stock Acquisition RightsEquivalent to 11.88% of the total 16,166 stock acquisition rights issued. Number of stock acquisition rights remaining unexercised as of the end of the previous month: 72,045; number remaining unexercised at present: 55,879
Most recent equity financingTiming 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company does not state a reason.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori